| Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results |
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. |
globenewswire.com |
2025-05-13 20:30:00 |
Czytaj oryginał (ang.) |
| Annovis Bio Appoints Hui Liu as Director of Biostatistics |
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. |
globenewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE |
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders' equity was less than $50 million. |
globenewswire.com |
2025-03-27 18:30:00 |
Czytaj oryginał (ang.) |
| Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program |
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results |
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. |
globenewswire.com |
2025-03-21 19:05:00 |
Czytaj oryginał (ang.) |
| Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment |
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer's & Parkinson's Drug Development Summit happening on March 18-20 in Boston, MA. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| Annovis to Host Patients' Live Forum on February 27, 2025 |
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families about the Company's clinical trials and future plans. |
globenewswire.com |
2025-02-19 10:30:00 |
Czytaj oryginał (ang.) |
| Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference |
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. |
globenewswire.com |
2025-02-07 10:00:00 |
Czytaj oryginał (ang.) |
| Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease |
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Annovis Bio, Inc. Announces Closing of $21 Million Public Offering |
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share and associated warrant. The warrants have an exercise price of $5.00 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter's discounts and other offering expenses, were $21 million. |
globenewswire.com |
2025-02-04 18:31:00 |
Czytaj oryginał (ang.) |
| Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering |
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The warrants will have an exercise price of $5.00 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be $21 million. The offering is expected to close on February 4, 2025, subject to satisfaction of customary closing conditions |
globenewswire.com |
2025-02-03 08:22:00 |
Czytaj oryginał (ang.) |
| Annovis Bio, Inc. Announces Proposed Public Offering |
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company. |
globenewswire.com |
2025-01-31 22:14:00 |
Czytaj oryginał (ang.) |
| Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection |
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. |
globenewswire.com |
2025-01-14 10:00:00 |
Czytaj oryginał (ang.) |
| Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace |
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio's (NYSE: ANVS) recent feature on Today's Marketplace (TMP) as part of its commitment to amplifying industry leaders' voices through targeted distribution channels. |
globenewswire.com |
2024-12-05 10:30:00 |
Czytaj oryginał (ang.) |
| /C O R R E C T I O N -- Today's Marketplace/ |
In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the company that in the Annovis boilerplate, the first sentence should include the stock ticker (NYSE: ANVS) as originally issued inadvertently. The complete, corrected release follows: Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace NEW YORK , Dec. 4, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Annovis' Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University's Institute for Population Health. |
prnewswire.com |
2024-12-04 16:21:00 |
Czytaj oryginał (ang.) |
| Annovis to Host Year-End Investor Webcast on December 11, 2024 |
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST. |
globenewswire.com |
2024-11-25 10:00:00 |
Czytaj oryginał (ang.) |
| IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio |
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. |
globenewswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs |
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy. |
globenewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases |
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition.” |
globenewswire.com |
2024-10-03 12:30:00 |
Czytaj oryginał (ang.) |
| Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations |
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. |
globenewswire.com |
2024-10-02 12:30:00 |
Czytaj oryginał (ang.) |
| Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference |
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. |
globenewswire.com |
2024-09-05 12:00:00 |
Czytaj oryginał (ang.) |
| Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist |
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease. |
globenewswire.com |
2024-08-06 12:00:00 |
Czytaj oryginał (ang.) |
| Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study |
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap. |
zacks.com |
2024-07-03 14:10:29 |
Czytaj oryginał (ang.) |
| Why Did Annovis Bio (ANVS) Stock Close Up 80% Today? |
Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions. |
investorplace.com |
2024-07-02 20:45:09 |
Czytaj oryginał (ang.) |
| Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial |
Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap. |
marketwatch.com |
2024-07-02 17:57:00 |
Czytaj oryginał (ang.) |
| Annovis Bio Files Patent for New Composition of Matter for Buntanetap |
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023. |
globenewswire.com |
2024-06-26 12:00:00 |
Czytaj oryginał (ang.) |
| Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients |
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. |
globenewswire.com |
2024-06-11 12:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet |
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-05-28 14:56:06 |
Czytaj oryginał (ang.) |
| Annovis Announces New Publication in a Peer-Reviewed Journal |
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. |
globenewswire.com |
2024-05-21 11:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors |
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of federal securities laws. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical. |
businesswire.com |
2024-05-17 15:00:00 |
Czytaj oryginał (ang.) |
| Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Annovis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,. |
businesswire.com |
2024-05-16 23:02:00 |
Czytaj oryginał (ang.) |
| The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the. |
businesswire.com |
2024-05-16 19:09:00 |
Czytaj oryginał (ang.) |
| Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results |
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. |
globenewswire.com |
2024-05-13 11:30:00 |
Czytaj oryginał (ang.) |